Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion. 2008

Lars-Olof Hattenbach, and Claudia Kuhli-Hattenbach, and Inge Scharrer, and Holger Baatz
Klinik für Augenheilkunde, Klinikum der Johann Wolfgang Goethe Universität, Frankfurt am Main, Germany. hattenbach.lo@klilu.de

OBJECTIVE To evaluate the beneficial effect of intravenous thrombolysis aiming at rapid restoration of blood flow during the early hours of a central retinal artery occlusion (CRAO). METHODS Interventional case series. METHODS In the present study, we prospectively evaluated the visual outcome after thrombolytic treatment with low-dose (50 mg) rt-PA (recombinant tissue plasminogen activator) and concomitant intravenous heparinization in patients with acute CRAO, best-corrected visual acuity (BCVA) < or = 20/100, and onset of symptoms within 12 hours prior to treatment. RESULTS Twenty-eight patients (28 eyes) were included in this study. Final visual acuity was improved three or more lines in nine eyes (32%), stable in 18 (64%), and worse in one eye. Time to treatment < or = 6.5 hours was associated with a better gain of lines of vision (P = .004). Seven of 17 eyes (41%) that received thrombolytic treatment within the first 6.5 hours achieved a final BCVA > or = 20/50, compared to none in the subgroup of patients with onset to treatment >6.5 hours (P = .023). We observed no serious adverse events. CONCLUSIONS Our findings indicate that thrombolytic treatment with intravenous low-dose rt-PA is of value for an improved visual recovery in patients with acute CRAO, if administered within the first 6.5 hours after the onset of symptoms.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D012161 Retinal Artery Central retinal artery and its branches. It arises from the ophthalmic artery, pierces the optic nerve and runs through its center, enters the eye through the porus opticus and branches to supply the retina. Central Retinal Artery,Arteries, Central Retinal,Arteries, Retinal,Artery, Central Retinal,Artery, Retinal,Central Retinal Arteries,Retinal Arteries,Retinal Arteries, Central,Retinal Artery, Central
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

Lars-Olof Hattenbach, and Claudia Kuhli-Hattenbach, and Inge Scharrer, and Holger Baatz
January 2021, The Journal of craniofacial surgery,
Lars-Olof Hattenbach, and Claudia Kuhli-Hattenbach, and Inge Scharrer, and Holger Baatz
September 2002, Archives of ophthalmology (Chicago, Ill. : 1960),
Lars-Olof Hattenbach, and Claudia Kuhli-Hattenbach, and Inge Scharrer, and Holger Baatz
November 2012, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association,
Lars-Olof Hattenbach, and Claudia Kuhli-Hattenbach, and Inge Scharrer, and Holger Baatz
June 2009, American journal of ophthalmology,
Lars-Olof Hattenbach, and Claudia Kuhli-Hattenbach, and Inge Scharrer, and Holger Baatz
March 2010, Stroke,
Lars-Olof Hattenbach, and Claudia Kuhli-Hattenbach, and Inge Scharrer, and Holger Baatz
October 2014, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie,
Lars-Olof Hattenbach, and Claudia Kuhli-Hattenbach, and Inge Scharrer, and Holger Baatz
December 1992, Archives of disease in childhood,
Lars-Olof Hattenbach, and Claudia Kuhli-Hattenbach, and Inge Scharrer, and Holger Baatz
February 2011, International journal of stroke : official journal of the International Stroke Society,
Lars-Olof Hattenbach, and Claudia Kuhli-Hattenbach, and Inge Scharrer, and Holger Baatz
January 1985, Journal of the American College of Cardiology,
Lars-Olof Hattenbach, and Claudia Kuhli-Hattenbach, and Inge Scharrer, and Holger Baatz
June 2019, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Copied contents to your clipboard!